An observational study in Cardiomyopathy, Hypertrophic, Cardiomyopathy, Dilated and Cardiomyopathy Restrictive, sponsored by Hospital do Coracao. Recruiting at 27 sites in Brazil. Per ClinicalTrials.gov, last updated 2026-05-08.
Sponsored by Hospital do Coracao · Observational
The goal of this observational study is to develop a registry of Brazilian patients with hereditary cardiovascular diseases, combining clinical and genomic data. The main questions it aims to answer are:
Which genes are most commonly affected? What is the frequency of these genetic alterations in our population? Participants will be interviewed in routine medical care visits and their DNA will be sequenced.
363 studies on the registry are indexed under Cardiomyopathy, Hypertrophic; 116 are open to participants now.
This study's planned enrollment of 1,211 is above the median of 259 across 174 observational studies indexed under Cardiomyopathy, Hypertrophic.
Browse Cardiomyopathy, Hypertrophic studies →Hospital do Coracao is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients under routine medical care in hospitals and clinics located in Brazil with a clinical diagnosis of an hereditary cardiovascular disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
whole genome sequencing of genomic DNA extracted from buccal swab
Diagnostic yield
Percentage of participants with pathogenic or likely pathogenic variants
Time frame: 30 months after study start date
Genetic diversity
Determine genes that cause hereditary cardiovascular diseases in Brazil
Time frame: 30 months after study start date
Variant frequency
Determine the frequency of disease-causing and benign variants in the Brazilian population
Time frame: 30 months after study start date
Plan to share: No — Genomic data are sensitve and will not be shared for individual participants
No publications or documents are linked to this record.
Started Apr 2025 (actual). Primary completion is estimated for Aug 2026, 16 months after the start.
Of 82 observational studies under Cardiomyopathy, Hypertrophic, half reached primary completion within 85 months of starting (the median), counting those still running; a quarter within 43. This study's planned 16 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cardiomyopathy, Hypertrophic →
Hospital do Coracao